Advertisement

Table of Contents

March 28, 2019; 133 (13)

EDITORIAL

BLOOD COMMENTARIES

PLENARY PAPER

REVIEW SERIES

CLINICAL TRIALS AND OBSERVATIONS

  • Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
    Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
    Gerwin Huls, Dana A. Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, Arjan A. van de Loosdrecht, Bart J. Biemond, Harm Sinnige, Beata Hodossy, Carlos Graux, Rien van Marwijk Kooy, Okke de Weerdt, Dimitri Breems, Saskia Klein, Jürgen Kuball, Dries Deeren, Wim Terpstra, Marie-Christiane Vekemans, Gert J. Ossenkoppele, Edo Vellenga, Bob Löwenberg and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

  • MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
    MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
    Alexander W. Koch, Nikolaus Schiering, Samu Melkko, Stefan Ewert, Janeen Salter, Yiming Zhang, Peter McCormack, Jianying Yu, Xueming Huang, Yu-Hsin Chiu, Zhiping Chen, Simone Schleeger, Geraldine Horny, Keith DiPetrillo, Lionel Muller, Andreas Hein, Frederic Villard, Meike Scharenberg, Paul Ramage, Ulrich Hassiepen, Serge Côté, Julie DeGagne, Carsten Krantz, Jörg Eder, Brian Stoll, Kenneth Kulmatycki, David L. Feldman, Peter Hoffmann, Craig T. Basson, Robert J. A. Frost and Yasser Khder

BLOOD WORK